Natco Pharma Completes Rights Issue Allotment of 1.7 Crore Shares

17,058,082 equity shares were allotted at ₹750 per share. Total paid-up equity capital rises to ₹39.23 crore post-allotment.

Reader Takeaway: Successful capital infusion strengthens balance sheet but increases equity dilution for existing shareholders.

What just happened

Natco Pharma Limited’s Fund Raising Committee met on October 23, 2026, to formally approve the allotment of 17,058,082 equity shares. These shares were issued through a rights issue mechanism at a price of ₹750 per share, which comprises a face value of ₹2 and a premium of ₹748.

Why this matters

The completion of this rights issue marks a key milestone in the company’s capital-raising initiative. With the issuance of these new shares, the total number of outstanding equity shares has moved from 179,109,870 to 196,167,952. The resulting increase in paid-up capital from ₹35.82 crore to ₹39.23 crore indicates a successful mobilization of funds from existing shareholders.

What changes now

For the company, the fresh capital provides liquidity to support its ongoing operations or strategic investments. For retail investors, the primary administrative task is to confirm that the allotted shares have been credited to their respective demat accounts. Investors should note the change in total share count, as this effectively dilutes the per-share earnings based on the expanded equity base.

What to track next

Shareholders should look for upcoming quarterly reports to see how the management deploys these new funds to drive operational growth or debt reduction. Additionally, monitor trading volumes, as the entry of these new shares into the secondary market could influence short-term price movements.